SG11202005208QA - Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma - Google Patents

Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma

Info

Publication number
SG11202005208QA
SG11202005208QA SG11202005208QA SG11202005208QA SG11202005208QA SG 11202005208Q A SG11202005208Q A SG 11202005208QA SG 11202005208Q A SG11202005208Q A SG 11202005208QA SG 11202005208Q A SG11202005208Q A SG 11202005208QA SG 11202005208Q A SG11202005208Q A SG 11202005208QA
Authority
SG
Singapore
Prior art keywords
cell lymphoma
cutaneous
composition
treating peripheral
treating
Prior art date
Application number
SG11202005208QA
Other languages
English (en)
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of SG11202005208QA publication Critical patent/SG11202005208QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202005208QA 2017-12-06 2018-12-05 Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma SG11202005208QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741043740 2017-12-06
PCT/IB2018/059680 WO2019111185A1 (en) 2017-12-06 2018-12-05 Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma

Publications (1)

Publication Number Publication Date
SG11202005208QA true SG11202005208QA (en) 2020-07-29

Family

ID=65012059

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005208QA SG11202005208QA (en) 2017-12-06 2018-12-05 Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma

Country Status (15)

Country Link
US (1) US20200289520A1 (zh)
EP (1) EP3720557A1 (zh)
JP (1) JP2021505571A (zh)
KR (1) KR20200096781A (zh)
CN (1) CN111770776A (zh)
AU (1) AU2018378415A1 (zh)
BR (1) BR112020011167A2 (zh)
CA (1) CA3084905A1 (zh)
CL (1) CL2020001482A1 (zh)
CO (1) CO2020006886A2 (zh)
EA (1) EA202091082A1 (zh)
IL (1) IL275028A (zh)
MX (1) MX2020005771A (zh)
SG (1) SG11202005208QA (zh)
WO (1) WO2019111185A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509992RA (en) * 2013-06-07 2016-01-28 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors
WO2021229452A1 (en) * 2020-05-14 2021-11-18 Rhizen Pharmaceuticals Ag Purine derivatives as sik-3 inhibitors
TW202241494A (zh) * 2021-02-10 2022-11-01 大陸商同潤生物醫藥(上海)有限公司 治療腫瘤的方法和組合
KR20230045895A (ko) * 2021-09-29 2023-04-05 사회복지법인 삼성생명공익재단 말초 t세포 림프종 예후 예측용 신규 바이오마커 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
JP5889795B2 (ja) * 2009-11-05 2016-03-22 ライゼン・ファーマシューティカルズ・エスアー 新規キナーゼモジュレーター
SG11201509992RA (en) 2013-06-07 2016-01-28 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors

Also Published As

Publication number Publication date
EA202091082A1 (ru) 2020-10-23
CO2020006886A2 (es) 2020-08-31
CL2020001482A1 (es) 2020-11-20
CA3084905A1 (en) 2019-06-13
JP2021505571A (ja) 2021-02-18
AU2018378415A1 (en) 2020-07-23
CN111770776A (zh) 2020-10-13
IL275028A (en) 2020-07-30
EP3720557A1 (en) 2020-10-14
BR112020011167A2 (pt) 2020-11-17
KR20200096781A (ko) 2020-08-13
MX2020005771A (es) 2020-10-28
WO2019111185A1 (en) 2019-06-13
US20200289520A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
EP3480323A4 (en) ROLL TREATMENT METHOD AND TREATMENT DEVICE FOR TOTAL STEEL SLAG TREATMENT
IL275028A (en) Preparation and method for the treatment of peripheral T-cell lymphoma and cutaneous T-cell lymphoma
IL251215A0 (en) Cannabinoid preparation and method for treating pain
IL279748A (en) Preparation and method for treating pain
EP3388196A4 (en) PROCESSING METHOD AND DEVICE FOR TREATING A SURFACE
EP3251317A4 (en) Device and method for effective use of unlicensed spectrum
EP3181744A4 (en) Treatment device and treatment method
EP3498387A4 (en) APPARATUS AND METHOD FOR TREATING INCINERATED ASHES
SG11201710053SA (en) Substrate treatment device and substrate treatment method
IL271256A (en) Preparations and methods for the treatment of teopathy
EP3574812A4 (en) EXCREMENT TREATMENT PROCESS AND CORRESPONDING DEVICE
EP3178899A4 (en) Antifouling composition, treatment device, treatment method, and treated article
SI3483304T1 (sl) Postopek in naprava za obdelavo površin
PL3263532T3 (pl) Urządzenie do przerobu mułku zgorzelinowego oraz sposób eksploatacji urządzenia do przerobu mułku zgorzelinowego
EP3605232A4 (en) TREATMENT METHOD AND TREATMENT DEVICE
EP3587033A4 (en) PROCESSING METHODS FOR SURFACE TREATMENT AND PROCESSING DEVICE FOR SURFACE TREATMENT
EP3302695A4 (en) Method and devices for treating muscles
EP3375568A4 (en) Surface treatment device and surface treatment method
IL271923A (en) Methods and compositions for treating addictions
GB201704736D0 (en) Treatment apparatus and method
EP3608295A4 (en) METHOD FOR TREATING ORGANIC WASTEWATER AND DEVICE FOR TREATING ORGANIC WASTEWATER
IL273805A (en) Preparations and methods for the treatment of diffuse large b-cell lymphoma
ZA202000407B (en) Device and method for treating must
EP3485823A4 (en) GRIPPING AND TREATMENT DEVICE
IL265387A (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan